TuHURA Biosciences, Inc.
HURAHealthcare|Biotechnology|US
$1.63
+0.02 (+1.24%)
Tangible Book / Share
$0.12
Cash / Share
$0.02
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06947928 Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | Advanced Or Metastatic Merkel Cell Carcinoma | P2P3 | Recruiting | 118 | RCT, Double-blind | IFx-Hu2.0, Placebo, Pembrolizumab |
| NCT06940440 IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | Advanced Or Metastatic Merkel Cell Carcinoma | P1 | Recruiting | 9 | Open-label | IFx-Hu2.0, Pembrolizumab |
| NCT04925713 IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | P1 | Completed | 5 | Open-label | IFx-Hu2.0 |
| NCT04160065 Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | P1 | Completed | 23 | Open-label | IFx-Hu2.0 |
| NCT03655756 pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | Early P1 | Completed | 7 | Open-label | IFx-Hu2.0 |
| NCT04853602 IFx-Hu2.0 Expanded Access Program | Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | AVAILABLE | — | — | IFx-Hu2.0 |